Prelude Therapeutics (PRLD) Competitors $0.80 +0.12 (+17.29%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.85 +0.05 (+6.79%) As of 03/28/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRLD vs. MOLN, CYBN, CCCC, SCPH, IVA, LRMR, GLSI, CGEN, ACTU, and HURAShould you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include Molecular Partners (MOLN), Cybin (CYBN), C4 Therapeutics (CCCC), scPharmaceuticals (SCPH), Inventiva (IVA), Larimar Therapeutics (LRMR), Greenwich LifeSciences (GLSI), Compugen (CGEN), Actuate Therapeutics (ACTU), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry. Prelude Therapeutics vs. Molecular Partners Cybin C4 Therapeutics scPharmaceuticals Inventiva Larimar Therapeutics Greenwich LifeSciences Compugen Actuate Therapeutics TuHURA Biosciences Prelude Therapeutics (NASDAQ:PRLD) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, community ranking, earnings, valuation, risk and media sentiment. Do analysts prefer PRLD or MOLN? Prelude Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 400.19%. Molecular Partners has a consensus target price of $12.00, indicating a potential upside of 180.96%. Given Prelude Therapeutics' higher possible upside, analysts plainly believe Prelude Therapeutics is more favorable than Molecular Partners.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prelude Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Molecular Partners 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more volatility & risk, PRLD or MOLN? Prelude Therapeutics has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Which has better earnings and valuation, PRLD or MOLN? Molecular Partners has lower revenue, but higher earnings than Prelude Therapeutics. Molecular Partners is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrelude Therapeutics$7M6.30-$121.83M-$1.69-0.47Molecular Partners$4.97M34.70-$69.04M-$1.81-2.36 Does the media favor PRLD or MOLN? In the previous week, Prelude Therapeutics had 4 more articles in the media than Molecular Partners. MarketBeat recorded 7 mentions for Prelude Therapeutics and 3 mentions for Molecular Partners. Prelude Therapeutics' average media sentiment score of 1.11 beat Molecular Partners' score of 0.47 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer PRLD or MOLN? Prelude Therapeutics received 17 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 49.18% of users gave Prelude Therapeutics an outperform vote while only 48.15% of users gave Molecular Partners an outperform vote. CompanyUnderperformOutperformPrelude TherapeuticsOutperform Votes3049.18% Underperform Votes3150.82% Molecular PartnersOutperform Votes1348.15% Underperform Votes1451.85% Is PRLD or MOLN more profitable? Prelude Therapeutics has a net margin of 0.00% compared to Molecular Partners' net margin of -1,043.01%. Molecular Partners' return on equity of -39.31% beat Prelude Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Prelude TherapeuticsN/A -66.89% -55.59% Molecular Partners -1,043.01%-39.31%-35.46% Do insiders & institutionals have more ownership in PRLD or MOLN? 79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 26.5% of Molecular Partners shares are owned by institutional investors. 62.8% of Prelude Therapeutics shares are owned by insiders. Comparatively, 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryPrelude Therapeutics beats Molecular Partners on 13 of the 19 factors compared between the two stocks. Remove Ads Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRLD vs. The Competition Export to ExcelMetricPrelude TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.11M$6.90B$5.63B$7.84BDividend YieldN/A2.77%5.33%4.01%P/E Ratio-0.457.2623.5818.74Price / Sales6.30218.62388.2390.77Price / CashN/A65.6738.1734.64Price / Book0.196.386.894.23Net Income-$121.83M$142.34M$3.20B$247.47M7 Day Performance12.54%-5.15%-3.06%-2.29%1 Month Performance5.36%-7.55%1.51%-5.81%1 Year Performance-83.13%-11.06%9.37%-0.96% Prelude Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRLDPrelude Therapeutics2.7576 of 5 stars$0.80+17.3%$4.00+400.2%-83.1%$44.11M$7M-0.45120Insider TradeNews CoveragePositive NewsGap UpHigh Trading VolumeMOLNMolecular Partners2.131 of 5 stars$3.97+0.9%$12.00+202.6%+1.7%$160.09M$4.97M-1.84180CYBNCybin2.3594 of 5 stars$7.34+0.3%$86.00+1,072.5%N/A$158.50MN/A-1.6850Positive NewsCCCCC4 Therapeutics2.5659 of 5 stars$2.25+5.9%$12.50+456.8%-78.6%$155.82M$35.58M-1.29150Positive NewsSCPHscPharmaceuticals3.9263 of 5 stars$3.11+3.6%$14.00+350.6%-44.6%$155.63M$36.33M-1.6330IVAInventiva2.037 of 5 stars$2.90+2.8%$12.60+334.5%-19.0%$151.13M$15.62M0.00100Analyst ForecastNews CoverageLRMRLarimar Therapeutics1.919 of 5 stars$2.27-10.8%$20.13+788.1%-69.0%$147.08MN/A-2.0030Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGLSIGreenwich LifeSciences2.0567 of 5 stars$11.13+0.2%$38.00+241.4%-48.7%$146.30MN/A-13.913News CoverageCGENCompugen1.997 of 5 stars$1.62+2.9%$4.00+147.7%-40.7%$144.12M$27.86M80.7570Positive NewsACTUActuate TherapeuticsN/A$7.30+8.1%$20.00+174.0%N/A$142.49MN/A0.0010HURATuHURA BiosciencesN/A$3.48+4.4%$13.00+274.1%N/A$140.98MN/A0.00N/A Remove Ads Related Companies and Tools Related Companies Molecular Partners Alternatives Cybin Alternatives C4 Therapeutics Alternatives scPharmaceuticals Alternatives Inventiva Alternatives Larimar Therapeutics Alternatives Greenwich LifeSciences Alternatives Compugen Alternatives Actuate Therapeutics Alternatives TuHURA Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRLD) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
